NCT04694560撤回不适用
A Phase 2 Time-Limited Approach to Front-Line Ibrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Patients Who Achieve Complete Remission or Partial Remission With Undetectable Minimal Residual Disease
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- Tumor Free Survival rate
研究概览
简要总结
The purpose of this study is to find out whether people with CLL or SLL who are currently receiving treatment with ibrutinib can stop treatment and remain off-treatment for at least 12 months, if they have achieved complete or partial remission of their disease.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •≥ 18-years-old
- •Diagnosis of CLL or SLL confirmed by the enrolling institution
- •Negative del(17p) test confirmed by FISH testing prior to initiating treatment with ibrutinib
- •Receiving commercial treatment with an ibrutinib-based regimen in the front-line setting as defined below with the intent to discontinue therapy on C1D1:
- •Ibrutinib monotherapy
- •Ibrutinib in combination with anti-CD20 monoclonal antibody (Patients must have completed the anti-CD20 monoclonal antibody portion of the regimen prior to signing consent)
- •Patients must have received ibrutinib-based therapy for at least 15 months. Dose interruptions and reductions during this treatment period may have been carried out per treating provider discretion.
- •Response evaluation performed by radiology assessment (CT or MRI imaging of neck / chest / abdomen / pelvis) confirming complete remission or partial remission by iwCLL criteria.
- •Peripheral blood (by flow cytometry per institutional standards) testing for MRD confirming U-MRD to a sensitivity of 10^-
- •MRD testing must be confirmed to follow ERIC consensus criteria.
- •CR with or without U-MRD in peripheral blood
- •PR with U-MRD in peripheral blood
排除标准
- •Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk..
- •Unwilling or unable to participate in all required study evaluations and procedures. Unable to understand the purpose and risks of the study and to provide a signed and dated informed consent form (ICF) and authorization to use protected health information (in accordance with national and local patient privacy regulations).
结局指标
主要结局
Tumor Free Survival rate
时间窗: At the end of Cycle 24 (each cycle is 28 days) cycles +/- 14 days
Participants will be evaluated by iwCLL / International Workshop on Chronic Lymphocytic Leukemia criteria
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
终止
2 期
RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) TrialChronic Lymphocytic LeukaemiaNCT01127542The Christie NHS Foundation Trust1
已完成
2 期
CLL Empirical Antibiotic RegimenChronic Lymphocytic Leukaemia (CLL)NCT01279252King's College Hospital NHS Trust71
招募中
2 期
DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8)Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaNCT06539182Dizal Pharmaceuticals155
已完成
3 期
Pneumococcal Vaccine in Untreated CLL PatientsChronic Lymphocytic LeukemiaNCT01892618Karolinska University Hospital134
终止
3 期
Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)Behavioral Variant Frontotemporal DementiaAlzheimer's DiseaseNCT02245568TauRx Therapeutics Ltd913